This study evaluated the noninferiority of replacing ethambutol with faropenem in 1st line treatment of drug-susceptible pulmonary TB. Faropenem achieved comparable treatment & microbiological outcomes with a more favorable safety profile & fewer AEs.
This presentation summarizes the key findings based on pulmonologists’ perspectives from a survey conducted to understand clinicians perspectives and practice patterns in both the diagnosis and treatment of group 1 and group 3 PH, which can further help optimize the management of PH patients.